NetworkNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD
Post# of 90
(Total Views: 128)
Posted On: 12/06/2023 2:55:20 PM
NetworkNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has released a fireside chat video with CEO and chair Howard Weisman. During the company update video, Weisman outlines the company’s recent achievement and reiterates PaxMedica’s focus on developing groundbreaking therapies and transformative solutions. Specifically, Weisman provided a summary of the company’s Oct. 25, 2023, FDA Type-B meeting, including the regulatory pathway for HAT-PAX-101. He also discussed the company’s successful $7 million public offering and the recent acquisition of suramin research assets from Rediscovery Life Sciences (“RLS”) as well as provided updates on the phase 3 trial for HAT-PAX-101 and plans for future autism spectrum disorder (“ASD”) trials. In addition, Weisman explained PaxMedica’s business strategy, placing particular emphasis on efficiency, production milestones and key partnerships, and the company’s future vision, including NDA plans for PAX-101 and potential advancements in autism treatment.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has released a fireside chat video with CEO and chair Howard Weisman. During the company update video, Weisman outlines the company’s recent achievement and reiterates PaxMedica’s focus on developing groundbreaking therapies and transformative solutions. Specifically, Weisman provided a summary of the company’s Oct. 25, 2023, FDA Type-B meeting, including the regulatory pathway for HAT-PAX-101. He also discussed the company’s successful $7 million public offering and the recent acquisition of suramin research assets from Rediscovery Life Sciences (“RLS”) as well as provided updates on the phase 3 trial for HAT-PAX-101 and plans for future autism spectrum disorder (“ASD”) trials. In addition, Weisman explained PaxMedica’s business strategy, placing particular emphasis on efficiency, production milestones and key partnerships, and the company’s future vision, including NDA plans for PAX-101 and potential advancements in autism treatment.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)